search
Back to results

Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy (PHOENIX)

Primary Purpose

Geographic Atrophy

Status
Recruiting
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Tinlarebant
Placebo
Sponsored by
Belite Bio, Inc
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Geographic Atrophy focused on measuring LBS-008, Tinlarebant, GA

Eligibility Criteria

60 Years - 85 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Subjects must have a confirmed diagnosis of GA with atrophic lesions in 1 or both eyes. Minimum BCVA is required in the study eye Exclusion Criteria: The presence of diabetic macular edema or macular disease in either eye. Diabetic retinopathy more advanced than mild nonproliferative diabetic retinopathy, or any other retinal vascular disease in either eye. Uncontrolled diagnosed glaucoma in the study eye

Sites / Locations

  • Belite Study Site
  • Belite Study SiteRecruiting
  • Belite Study SiteRecruiting
  • Belite Study Site
  • Belite Study Site
  • Belite Study SiteRecruiting
  • Belite Study SiteRecruiting
  • Belite Study Site
  • Belite Study Site
  • Belite Study Site

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

LBS-008, Tinlarebant

Placebo

Arm Description

Outcomes

Primary Outcome Measures

To measure the rate of change (growth rate slope) in geographic atrophy (GA) lesion size

Secondary Outcome Measures

To measure the change in best-corrected visual acuity (BCVA) as assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) scale
To measure changes in the area and size of the inner/outer segment junction of photoreceptors by spectral domain optical coherence tomography (SD-OCT)

Full Information

First Posted
July 10, 2023
Last Updated
September 27, 2023
Sponsor
Belite Bio, Inc
search

1. Study Identification

Unique Protocol Identification Number
NCT05949593
Brief Title
Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy
Acronym
PHOENIX
Official Title
PHase 3, Multicenter, RandOmized, Double-masked, PlacEbo-CoNtrolled Study of TInlarebant to EXplore Safety and Efficacy in the Treatment of Geographic Atrophy (the PHOENIX Study)
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
July 27, 2023 (Actual)
Primary Completion Date
August 31, 2027 (Anticipated)
Study Completion Date
November 30, 2027 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Belite Bio, Inc

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This Phase 3, multicenter, double-masked, parallel-group, placebo-controlled, randomized, fixed-dose clinical study is designed to evaluate the efficacy and safety of tinlarebant (LBS-008) in subjects diagnosed with GA.
Detailed Description
Subjects will be randomized in a 2:1 ratio to receive either tinlarebant or placebo. The study treatment will be administered orally once daily from baseline (Day 1) through the final day of Month 24.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Geographic Atrophy
Keywords
LBS-008, Tinlarebant, GA

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Masking Description
Eligible subjects will be randomly assigned to begin treatment in 2:1 ratio to receive the study drug (either Tinlarebant 5 mg or matching placebo)
Allocation
Randomized
Enrollment
429 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
LBS-008, Tinlarebant
Arm Type
Experimental
Arm Title
Placebo
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
Tinlarebant
Intervention Description
5 mg tablet taken orally once a day
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo tablets for tinlarebant 5 mg prepared similarly.
Primary Outcome Measure Information:
Title
To measure the rate of change (growth rate slope) in geographic atrophy (GA) lesion size
Time Frame
From baseline to Month 24]
Secondary Outcome Measure Information:
Title
To measure the change in best-corrected visual acuity (BCVA) as assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) scale
Time Frame
From baseline to Month 24
Title
To measure changes in the area and size of the inner/outer segment junction of photoreceptors by spectral domain optical coherence tomography (SD-OCT)
Time Frame
From baseline to Month 24

10. Eligibility

Sex
All
Minimum Age & Unit of Time
60 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Subjects must have a confirmed diagnosis of GA with atrophic lesions in 1 or both eyes. Minimum BCVA is required in the study eye Exclusion Criteria: The presence of diabetic macular edema or macular disease in either eye. Diabetic retinopathy more advanced than mild nonproliferative diabetic retinopathy, or any other retinal vascular disease in either eye. Uncontrolled diagnosed glaucoma in the study eye
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Belitebio Clinical Operations
Phone
+886 972 080 097
Email
clinicaltrial@belitebio.com
Facility Information:
Facility Name
Belite Study Site
City
Arcadia
State/Province
California
ZIP/Postal Code
91007
Country
United States
Individual Site Status
Not yet recruiting
Facility Name
Belite Study Site
City
Huntington Beach
State/Province
California
ZIP/Postal Code
92467
Country
United States
Individual Site Status
Recruiting
Facility Name
Belite Study Site
City
Hagerstown
State/Province
Maryland
ZIP/Postal Code
21740
Country
United States
Individual Site Status
Recruiting
Facility Name
Belite Study Site
City
Westbury
State/Province
New York
ZIP/Postal Code
11590
Country
United States
Individual Site Status
Not yet recruiting
Facility Name
Belite Study Site
City
Portland
State/Province
Oregon
ZIP/Postal Code
97239
Country
United States
Individual Site Status
Not yet recruiting
Facility Name
Belite Study Site
City
Germantown
State/Province
Tennessee
ZIP/Postal Code
38138
Country
United States
Individual Site Status
Recruiting
Facility Name
Belite Study Site
City
Abilene
State/Province
Texas
ZIP/Postal Code
79606
Country
United States
Individual Site Status
Recruiting
Facility Name
Belite Study Site
City
Strathfield
State/Province
New South Wales
ZIP/Postal Code
2135
Country
Australia
Individual Site Status
Not yet recruiting
Facility Name
Belite Study Site
City
Taichung
ZIP/Postal Code
40447
Country
Taiwan
Individual Site Status
Not yet recruiting
Facility Name
Belite Study Site
City
Taoyuan
ZIP/Postal Code
33305
Country
Taiwan
Individual Site Status
Not yet recruiting

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy

We'll reach out to this number within 24 hrs